

Press Release

Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026

February 10, 2026 – release at 7:30 am
Sophia Antipolis, France

Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that phase 3 clinical study results, including two podium presentations, will be delivered at the upcoming American Glaucoma Society (AGS) Annual Meeting 2026 (February 19-22, 2026, Rancho Mirage, CA, U.S.A.).

“The opportunity to present data from our phase 3 studies with NCX 470, including two high-profile podium presentations, at the upcoming American Glaucoma Society (AGS) Annual Conference highlights the enormous strides Nicox has made to confirm the medical effectiveness of this novel product. The recognition comes at an important time as we prepare the regulatory submissions for NCX 470 in the U.S. and China with our licensees, Kowa and Ocumension, respectively,” said Doug Hubatsch, EVP and Chief Scientific Officer of Nicox. “The AGS conference offers an opportunity for more detailed analysis of data supporting the efficacy, safety, and mechanism of action of NCX 470 to be presented to glaucoma specialist eyecare practitioners at a leading event by well-known and respected Key Opinion Leaders.”

AGS 2026 Annual Meeting – February 19 to February 22, 2026, Rancho Mirage, CA, U.S.

Presentation Details

Title: A Randomized Trial Comparing NCX 470 0.1%, a Nitric Oxide-Donating Bimatoprost, and Latanoprost 0.005% for Open-Angle Glaucoma or Ocular Hypertension: The DENALI Trial

Type: Podium presentation session

Date: Friday, February 20, 2026 at 10:15 am (local time) during the Basic Science, Genetics, Novel Developments Paper Session.

Presenter: Dr. S. Asrani, Duke University Medical Center, Durham, NC

Title: Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution (Nitric Oxide-Donating Bimatoprost): A Double-Masked, Placebo-Controlled, Phase 3b Clinical Trial

Type: Podium presentation session

Date: Friday, February 20, 2026 at 10:25 am (local time) during the Basic Science, Genetics, Novel Developments Paper Session.

Presenter: Dr. A. Sit, Mayo Clinic, Rochester, Minnesota

Title: Outcomes in the United States Subgroup of the Denali Trial: A Randomized Trial Comparing NCX 470 0.1%, a Nitric Oxide-Donating Bimatoprost, and Latanoprost 0.005% for Open-Angle Glaucoma or Ocular Hypertension

Type: Poster presentation session

Date: Friday February 20, 2026 from 7:30 am to 8:30 am (local time).

Presenter: Dr. J. Bacharach, North Bay Eye Associates, Inc., Petaluma, CA

Members of the Nicox team will be available for one-on-one meetings. If you wish to set up a meeting, please contact us at communications@nicox.com.

About Nicox

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox's first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX).

For more information www.nicox.com

Analyst coverage

H.C. Wainwright & Co Yi Chen New York, U.S.



The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Contacts

Nicox

Gavin Spencer
Chief Executive Officer
T +33 (0)4 97 24 53 00
communications@nicox.com

Disclaimer

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in section 3 of the "Rapport Annuel 2024" and in section 4 of the "Rapport semestriel 2025" which are available on Nicox's website (www.nicox.com).

Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.

Nicox S.A.

Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, France
T +33 (0)4 97 24 53 00